Literature DB >> 22684565

Effect of early intensive insulin therapy on immune function of aged patients with severe trauma.

Junxun Ma1, Xiaodong Zhao2, Qin Su1, Wei Dang1, Xian Zhang1, Xiaoling Yuan1, Jianbo Zhang1, Hongsheng Liu1, Yuhong Qin1, Yongming Yao1, Hong Shen3.   

Abstract

This study examined the effect of intensive insulin therapy on immune function and inflammatory factors at the early phase after severe trauma. At day 1, 3, 5, 7 after admission, subsets of CD4(+) helper T lymphocytes (Th1/Th2) and human leukocyte antigen (HLA)-DR expression on CD14(+) monocytes were flow cytometrically measured. Levels of cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-10 (IL-10) and other immunity markers, such as IgA, IgG, IgM, C3, C4 and C reaction protein (CRP) were examined in two groups. The results showed that TNF-α, IL-6 and CRP levels in the intensive insulin therapy group were significantly lower than those in the conventional therapy group, whereas IL-10 levels were substantially increased after intensive insulin therapy. C3 level at day 3, 5, 7 and C4 levels at day 5, 7 were lower in the intensive therapy group than in the conventional therapy group. Th1/Th2 ratios decreased gradually over time in both groups, and were much lower at day 3, 5, 7 in intensive therapy group. There were significant differences among day 3 to day 7 after admission in HLA-DR expression in CD14(+) monocytes. It was concluded that the intensive insulin therapy could decrease pro-inflammatory cytokines and increase anti-inflammatory cytokines in the elderly suffering from severe trauma, at the same time, with complement recovery being delayed. Moreover, intensive insulin therapy promoted immune suppression and, therefore, measures need be taken to address the issue.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684565     DOI: 10.1007/s11596-012-0069-8

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  18 in total

1.  Intensive insulin therapy in the medical ICU.

Authors:  Greet Van den Berghe; Alexander Wilmer; Greet Hermans; Wouter Meersseman; Pieter J Wouters; Ilse Milants; Eric Van Wijngaerden; Herman Bobbaers; Roger Bouillon
Journal:  N Engl J Med       Date:  2006-02-02       Impact factor: 91.245

2.  Insulin therapy in the intensive care unit should be targeted to maintain blood glucose between 4.4 mmol/l and 6.1 mmol/l.

Authors:  G Van den Berghe
Journal:  Diabetologia       Date:  2007-11-27       Impact factor: 10.122

3.  Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient.

Authors:  M J Hershman; W G Cheadle; S R Wellhausen; P F Davidson; H C Polk
Journal:  Br J Surg       Date:  1990-02       Impact factor: 6.939

4.  Survival benefits of intensive insulin therapy in critical illness: impact of maintaining normoglycemia versus glycemia-independent actions of insulin.

Authors:  Björn Ellger; Yves Debaveye; Ilse Vanhorebeek; Lies Langouche; Annapaula Giulietti; Evelyne Van Etten; Paul Herijgers; Chantal Mathieu; Greet Van den Berghe
Journal:  Diabetes       Date:  2006-04       Impact factor: 9.461

Review 5.  Blood glucose control in the trauma patient.

Authors:  James Eakins
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

6.  CD14 expression in injured patients correlates with outcome.

Authors:  M Heinzelmann; M Mercer-Jones; W G Cheadle; H C Polk
Journal:  Ann Surg       Date:  1996-07       Impact factor: 12.969

7.  Burn-activated neutrophils and tumor necrosis factor-alpha alter endothelial cell actin cytoskeleton and enhance monolayer permeability.

Authors:  K Wright; F Nwariaku; N Halaihel; C Schulman; H L Yin; R H Turnage
Journal:  Surgery       Date:  2000-08       Impact factor: 3.982

8.  HLA-DR expression and soluble HLA-DR levels in septic patients after trauma.

Authors:  M Ditschkowski; E Kreuzfelder; V Rebmann; S Ferencik; M Majetschak; E N Schmid; U Obertacke; H Hirche; U F Schade; H Grosse-Wilde
Journal:  Ann Surg       Date:  1999-02       Impact factor: 12.969

9.  [Effects of intensive insulin therapy on serum immunoglobulin, complement levels and phagocytosis of monocytes in patients with severe trauma].

Authors:  Xiao-dong Zhao; Yong-ming Yao; Jun-xun Ma; Hua-ping Liang; Rui-min Yan; Lian-yang Zhang; Zhan-liang Li; Zhong-jie He; Qun Deng; Jun-dong Du; Bo-gang Yan
Journal:  Zhongguo Wei Zhong Bing Ji Jiu Yi Xue       Date:  2007-05

10.  Systems initiatives reduce healthcare-associated infections: a study of 22,928 device days in a single trauma unit.

Authors:  Richard S Miller; Patrick R Norris; Judith M Jenkins; Thomas R Talbot; John M Starmer; Sarah A Hutchison; Devin S Carr; Christopher J Kleymeer; John A Morris
Journal:  J Trauma       Date:  2010-01
View more
  4 in total

1.  Cyclooxygenase-2 blockade inhibits accumulation and function of myeloid-derived suppressor cells and restores T cell response after traumatic stress.

Authors:  Ren-Jie Li; Lin Liu; Wei Gao; Xian-Zhou Song; Xiang-Jun Bai; Zhan-Fei Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-04-08

2.  Influence of intensive insulin therapy on vascular endothelial growth factor in patients with severe trauma.

Authors:  Xiao-Dong Zhao; Yu-Hong Qin; Jun-Xun Ma; Wei Dang; Man Wang; Xian Zhang; Hong-Sheng Liu; Jian-Bo Zhang; Yong-Ming Yao; Lian-Yang Zhang; Qin Su
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-02-08

3.  Effects of intensive insulin therapy combined with low molecular weight heparin anticoagulant therapy on severe pancreatitis.

Authors:  Jun-Dong DU; Xi Zheng; Zhi-Qiang Huang; Shou-Wang Cai; Jing-Wang Tan; Zhan-Liang Li; Yong-Ming Yao; Hua-Bo Jiao; Hui-Nan Yin; Zi-Man Zhu
Journal:  Exp Ther Med       Date:  2014-04-25       Impact factor: 2.447

4.  The effect of short-term intensive insulin therapy on inflammatory cytokines in patients with newly diagnosed type 2 diabetes.

Authors:  Junyu He; Peiji Dai; Liyi Liu; Yanqing Yang; Xibo Liu; Yanbing Li; Zhihong Liao
Journal:  J Diabetes       Date:  2022-01-18       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.